Home
Traws Pharma

Traws Pharma Market Share Analysis for May 2026

Targeting escape mutations in hematological cancers with first and best in class medicines.

Industry: N/A

Domaintrawspharma.com

Year Founded--

Employees51 - 200

Annual Revenue--

Traws Pharma

Traws Pharma (including company regionals)

trawspharma.com

See more website traffic and engagement information

Total visits to Traws Pharma's top domains

Understand Traws Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

trawspharma.com4.4K

See more with Sales Intelligence

Avg. visit duration in Traws Pharma's top domains

Analyze Traws Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

trawspharma.com00:00:12

See more with Sales Intelligence

Avg. pageviews on Traws Pharma's top domains

See how Traws Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

trawspharma.com1.63

See more with Sales Intelligence

Traws Pharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Traws Pharma

These are the website technologies, by industry, used by Traws Pharma top domains

Payment & Currencies (3)

Cart Functionality

Conversion & Analytics (2)

Google Analytics

eCommerce (2)

Swap

Email Services (2)

G Suite

More Technologies

7

See all

News & Signals from Traws Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTraws Pharma, Inc. is developing broad-spectrum antiviral combination therapy on May 27th '26.Traws Pharma Inc. said May 27 that it is advancing development of a proprietary broad-spectrum antiviral combination therapy aimed at combating deadly viruses, including Hantavirus, Ebola, and Lassa fever.

NewsTraws Pharma, Inc. received financing of $10M on Apr 15th '26.NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE) - Traws Pharma, Inc. (NASDAQ: TRAW, "Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that it has entered into a securities purchase agreement with new and existing institutional and accredited investors for a private investment in public equity ("PIPE") financing expected to provide approximately $10.0 million in gross proceeds at closing.

NewsTraws Pharma, Inc. is developing novel influenza antiviral.hVIVO (AIM: HVO) has signed a clinical trial agreement with Nasdaq-listed Traws Pharma to conduct a human challenge trial testing a novel influenza antiviral, in a deal that underscores continued commercial momentum for the Canary Wharf-based specialist.